NX 001

Drug Profile

NX 001

Alternative Names: NX001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator NephRx Corporation
  • Class Growth factors; Peptides
  • Mechanism of Action Growth factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function

Highest Development Phases

  • No development reported Delayed graft function

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Delayed-graft-function(Prevention, In volunteers) in USA
  • 11 Nov 2010 NephRx Corporation receives Qualifying Therapeutic Discovery Project grant under the Patient Protection and Affordable Care Act of 2010 (PPACA)
  • 11 Nov 2010 Phase-I clinical trials in Delayed graft function in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top